Menu
Search
|

Menu

Close
X

Novelion Therapeutics Inc NVLN.OQ (NASDAQ Stock Exchange Global Select Market)

3.63 USD
-0.17 (-4.47%)
As of Jun 21
chart
Previous Close 3.80
Open 3.79
Volume 18,401
3m Avg Volume 11,609
Today’s High 3.79
Today’s Low 3.60
52 Week High 10.67
52 Week Low 3.10
Shares Outstanding (mil) 18.65
Market Capitalization (mil) 131.10
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
27
FY17
138
FY16
14
FY15
0
EPS (USD)
FY18
-1.755
FY17
-6.806
FY16
-4.601
FY15
-2.216
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.74
Price to Sales (TTM)
vs sector
1.55
5.71
Price to Book (MRQ)
vs sector
1.50
5.37
Price to Cash Flow (TTM)
vs sector
--
23.32
Total Debt to Equity (MRQ)
vs sector
277.18
16.46
LT Debt to Equity (MRQ)
vs sector
277.18
12.19
Return on Investment (TTM)
vs sector
-38.22
14.38
Return on Equity (TTM)
vs sector
-93.63
16.08

EXECUTIVE LEADERSHIP

Jason Aryeh
Independent Chairman of the Board, Since 2012
Salary: --
Bonus: --
Michael Price
Chief Financial Officer, Senior Vice President, Since 2017
Salary: --
Bonus: --
Jeffrey Hackman
Chief Operating Officer, Executive Vice President, Since 2017
Salary: --
Bonus: --
Barbara Chan
Chief Accounting Officer, Since 2016
Salary: --
Bonus: --
Suzanne Bruhn
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1800-510 Georgia St W
VANCOUVER   BC   V6B 0M3

Phone: +1604.7077000

Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company's portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

SPONSORED STORIES